EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Urodynamic and Anamnestic Predictors for Individual Dose Adjustment of Intravesical Oxybutynin in Neurogenic Detrusor Overactivity: Results From the UPSIDE Study

Arndt Van Ophoven iD, Severine Banek, Kristin Becker iD, Markus Heibel, Almut Hirsch, Margot Kieruj iD, Ines Kurze iD, Anja Lingnau iD, Barbara Ludwikowski iD, Tobias Luithle iD, Fabian Queissert iD, Wolfgang Rösch und 5 weitere

Neurourology and Urodynamics · 2026-09 · 45 (7) · 1319-1327

DOI: 10.1002/nau.70329 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Neurourology and Urodynamics, online erschienen am 22.06.2026. Verfasst von Arndt Van Ophoven und 16 weiteren Autor:innen. Beteiligte Einrichtung: Marien Hospital Herne Universitätsklinikum der Ruhr-Universität, Herne, Germany. Hauptthemen laut MEDLINE: Mandelic Acids, Muscarinic Antagonists, Urinary Bladder, Neurogenic, Urinary Bladder, Overactive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Farco Pharma GmbH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Intravesical oxybutynin (IVO) is a 2nd line treatment option for patients with neurogenic detrusor overactivity (NDO) who are not adequately managed by oral anticholinergics. The UPSIDE study aimed to identify urodynamic and anamnestic predictors for achieving a therapeutically satisfactory dose (TSD) of 1 mg/mL IVO and to evaluate treatment outcomes including continence, quality of life (QoL), adherence, and handling.

Methods

UPSIDE was a prospective, multicentre, non‐interventional, real‐world study including paediatric (age ≥ 6) and adult patients with NDO due to spinal cord injury (SCI), spina bifida (SB), or multiple sclerosis (MS). Patients switched to IVO (VESOXX) were observed for at least 3 months. The primary endpoint was achievement of a TSD. Secondary endpoints included urodynamic changes, continence, spontaneous micturition, catheter volume, urinary tract infections (UTI), QoL (SF‐Qualiveen‐questionnaire), adherence, persistence, handling, pre‐ and concomitant therapies and safety.

Results

Of 54 patients enrolled across 14 study centres, 36 formed the full analysis set, and 26 (72%) were categorized with a TSD. Older age and reduced estimated glomerular filtration rate (eGFR) were identified as predictors for TSD ( p = 0.059; p = 0.011, respectively). A dose adaptation was necessary for almost every second patient (47.2%). Urodynamic parameters such as p det max and bladder compliance improved. Maximal catheter volume increased significantly from 304 to 409 mL ( p = 0.012). Continence rates doubled (28% to 53%, p = 0.043), spontaneous micturition increased from 33% to 42% (observed exclusively in patients with MS), daily micturition frequency decreased statistically significant from 8.3 to 4.6 ( p = 0.008, n = 12, n = 14 respectively). UTIs decreased from 42% to 25%. SF‐Qualiveen improved statistically significant by 25% ( p = 0.03). 70% of patients rated handling of the prefilled syringe as easy or very easy. Adherence and persistence exceeded 80%. No therapy‐related serious adverse events were reported.

Conclusion

VESOXX was effective in improving urodynamic parameters, continence, QoL, reduction of UTI and handling experience in NDO patients, with high adherence and no therapy‐related serious adverse events. TSD prediction is associated with older age and reduced eGFR. UPSIDE provides clinically relevant guidance for individualized intravesical therapy; however, interpretation of pressure‐based safety targets should remain cautious within the context of this pragmatic real‐world study. Trial Registration: The UPSIDE non‐interventional trial is registered in the German clinical study registry DRKS under the number: DRKS00028775.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mandelic AcidsMuscarinic AntagonistsUrinary Bladder, NeurogenicUrinary Bladder, OveractiveUrological AgentsAdolescentAdultChildFemaleHumansMaleMiddle AgedYoung AdultAdministration, IntravesicalProspective StudiesQuality of LifeTreatment OutcomeUrinary BladderUrodynamics

Stichwörter der Autor:innen

NLUTDadherenceanticholinergicscontinencedose adjustmentintravesical oxybutyninneurogenic bladderneurogenic detrusor overactivityquality of lifeurodynamics

Substanzen

Mandelic AcidsMuscarinic AntagonistsoxybutyninUrological Agents

Autor:innen und Institutionen

  • Marien Hospital Herne Universitätsklinikum der Ruhr-Universität, Herne, Germany.
  • Universitäts Medizin Frankfurt, Klinik für Urologie, Frankfurt am Main, Germany.
  • Haunersches Kinderspital, Kinderchirurgische Klinik und Poliklinik, München, Germany.
  • Sauerlandklinik Hachen gGmbH, Sundern, Germany.
  • Klinik Hallerwiese-Cnopfsche Kinderklinik, Kinderneurologie, Nürnberg, Germany.
  • DRK Kamillus Klinik Asbach, Asbach, Germany.

ORCID-Profile: Arndt Van Ophoven, Kristin Becker, Margot Kieruj, Ines Kurze, Anja Lingnau, Barbara Ludwikowski, Tobias Luithle, Fabian Queissert, Regina Stredele, Thomas Michael Karl Völkl, Quentin Leidl, Michael Gedamke

Förderung

  • Farco Pharma GmbH

Zitieren

APA

Van Ophoven, A., Banek, S., Becker, K., Heibel, M., Hirsch, A., Kieruj, M., Kurze, I., Lingnau, A., Ludwikowski, B., Luithle, T., Queissert, F., Rösch, W., Schindler, O., Stredele, R., Völkl, T. M. K., Leidl, Q., & Gedamke, M. (2026). Urodynamic and Anamnestic Predictors for Individual Dose Adjustment of Intravesical Oxybutynin in Neurogenic Detrusor Overactivity: Results From the UPSIDE Study. Neurourology and Urodynamics, 45(7), 1319-1327. https://doi.org/10.1002/nau.70329

Vancouver

Van Ophoven A, Banek S, Becker K, Heibel M, Hirsch A, Kieruj M, et al. Urodynamic and Anamnestic Predictors for Individual Dose Adjustment of Intravesical Oxybutynin in Neurogenic Detrusor Overactivity: Results From the UPSIDE Study. Neurourology and Urodynamics. 2026;45(7):1319-1327. doi:10.1002/nau.70329

BibTeX
@article{VanOphoven2026,
  author = {Van Ophoven, Arndt and Banek, Severine and Becker, Kristin and Heibel, Markus and Hirsch, Almut and Kieruj, Margot and Kurze, Ines and Lingnau, Anja and Ludwikowski, Barbara and Luithle, Tobias and Queissert, Fabian and Rösch, Wolfgang and Schindler, Oliver and Stredele, Regina and Völkl, Thomas Michael Karl and Leidl, Quentin and Gedamke, Michael},
  title = {Urodynamic and Anamnestic Predictors for Individual Dose Adjustment of Intravesical Oxybutynin in Neurogenic Detrusor Overactivity: Results From the UPSIDE Study},
  journal = {Neurourology and Urodynamics},
  year = {2026},
  volume = {45},
  number = {7},
  pages = {1319--1327},
  doi = {10.1002/nau.70329}
}
Kostenlos starten →